Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.

  • Revenue in USD (TTM)53.20bn
  • Net income in USD7.32bn
  • Incorporated1994
  • Employees84.59k
  • Location
    Sanofi SA46 Avenue de la Grande ArmeePARIS 75017FranceFRA
  • Phone+33 153774000
  • Fax+33 153774463
  • Websitehttps://www.sanofi.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
SAN:PAR since
announced
Transaction
value
Blueprint Medicines CorpAnnounced02 Jun 202502 Jun 2025Announced-4.83%9.10bn
Vigil Neuroscience IncAnnounced21 May 202521 May 2025Announced-10.94%466.72m
Data delayed at least 15 minutes, as of Jul 04 2025 16:36 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Zoetis Inc9.29bn2.52bn70.87bn13.80k28.5815.2523.487.635.575.5720.5410.440.65291.077.00672,898.6017.7715.2521.8318.3170.9870.1827.2226.321.0421.140.585628.938.338.146.0610.637.3221.37
Bristol-Myers Squibb Co47.64bn5.42bn95.49bn34.10k17.615.497.062.002.662.6623.448.540.49764.275.121,396,950.005.680.65367.690.817574.6976.6311.411.521.177.390.7402678.247.3213.06-211.50--8.347.91
Vertex Pharmaceuticals Inc11.10bn-988.90m118.03bn6.10k--7.16--10.63-3.88-3.8842.8664.200.47441.436.171,819,623.00-4.2314.06-5.0416.6786.0387.35-8.9126.282.29--0.00670.0011.6621.50-114.80--45.11--
Sanofi SA (ADR)53.20bn7.32bn120.44bn84.59k16.551.3913.112.262.922.9621.2834.80------628,897.50--6.12--7.5470.9469.2313.5917.970.68826.880.2205--6.413.318.5714.0012.32--
Gilead Sciences Inc28.74bn5.97bn139.01bn17.60k23.647.2615.914.844.734.7322.7915.390.50983.456.351,632,671.0010.585.2613.636.3878.2978.4720.7612.541.237.800.5667108.476.045.08-91.53-38.34-8.714.10
Pfizer Inc62.46bn7.87bn144.29bn81.00k18.411.609.752.311.381.3810.9515.890.29111.465.47771,148.103.687.454.499.4374.5769.1012.6420.370.960412.260.406664.226.849.10275.82-5.272.323.13
Amgen Inc34.13bn5.93bn160.37bn28.00k27.2225.8413.904.7010.9610.9663.0511.540.37431.594.581,218,786.006.518.438.5010.6664.0772.8117.3921.900.8787.060.902471.3718.577.43-39.11-12.2112.149.18
Data as of Jul 03 2025. Currency figures normalised to Sanofi SA's reporting currency: US Dollar USD

Institutional shareholders

5.87%Per cent of shares held by top holders
HolderShares% Held
Dodge & Coxas of 31 Mar 202573.19m2.97%
Fisher Asset Management LLCas of 31 Mar 202513.57m0.55%
Invesco Advisers, Inc.as of 31 Mar 202511.31m0.46%
T. Rowe Price Associates, Inc. (IM)as of 31 Mar 202511.03m0.45%
Capital Research & Management Co. (World Investors)as of 31 Mar 20258.32m0.34%
Managed Account Advisors LLCas of 31 Mar 20257.57m0.31%
Barrow, Hanley, Mewhinney & Strauss LLCas of 31 Mar 20257.35m0.30%
Wellington Management Co. LLPas of 31 Mar 20254.38m0.18%
Boston Partners Global Investors, Inc.as of 31 Mar 20254.09m0.17%
Parametric Portfolio Associates LLCas of 31 Mar 20254.04m0.16%
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.